Both LRP1B and FRMD3 serve as TSGs in brain tumors, and some research has shown that LRP1B deletion affects the prognosis of malignant brain neoplasms, including GBM and medulloblastoma, in the U.S. population according to TCGA data [39,40,41]. Here, LRP1B is linked to brain cancer.